These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 23698805)

  • 21. Role of the renin-angiotensin-aldosterone system in vascular remodeling and inflammation: a clinical review.
    Duprez DA
    J Hypertens; 2006 Jun; 24(6):983-91. PubMed ID: 16685192
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Novel therapies blocking the renin-angiotensin-aldosterone system in the management of hypertension and related disorders.
    Krum H; Gilbert RE
    J Hypertens; 2007 Jan; 25(1):25-35. PubMed ID: 17143168
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Targeting the renin-angiotensin system for the reduction of cardiovascular outcomes in hypertension: angiotensin-converting enzyme inhibitors and angiotensin receptor blockers.
    Kjeldsen SE; Lyle PA; Tershakovec AM; Devereux RB; Oparil S; Dahlöf B; de Faire U; Fyhrquist F; Ibsen H; Kristianson K; Lederballe-Pedersen O; Lindholm LH; Nieminen MS; Omvik P; Wedel H
    Expert Opin Emerg Drugs; 2005 Nov; 10(4):729-45. PubMed ID: 16262560
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Hypertension and depressed symptomatology: a cluster related to the activation of the renin-angiotensin-aldosterone system (RAAS). Findings from population based KORA F4 study.
    Häfner S; Baumert J; Emeny RT; Lacruz ME; Bidlingmaier M; Reincke M; Ladwig KH
    Psychoneuroendocrinology; 2013 Oct; 38(10):2065-74. PubMed ID: 23608138
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Angiotensin receptor blockers: novel role in high-risk patients.
    Javed U; Deedwania PC
    Cardiol Clin; 2008 Nov; 26(4):507-26. PubMed ID: 18929228
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Pathophysiological role of tissue renin-angiotensin-aldosterone system (RAAS) in human atherosclerosis].
    Fukui K; Yamada H; Matsubara H
    Nihon Rinsho; 2012 Sep; 70(9):1556-61. PubMed ID: 23012803
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Renoprotection by blockade of the renin-angiotensin-aldosterone system in diabetic and non-diabetic chronic kidney disease. Specific involvement of intra-renal angiotensin-converting enzyme activity in therapy resistance?
    Vogt L; Kocks MJ; Laverman GD; Navis G
    Minerva Med; 2004 Oct; 95(5):395-409. PubMed ID: 15467515
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Oral inhibitors of renin and their potential use as therapeutic agents in treating hypertension].
    Abassi Z; Armaly Z; Nakhoul F; Hoffman A
    Harefuah; 2008 Jun; 147(6):536-42, 573. PubMed ID: 18693632
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Aliskiren in the treatment of hypertension and organ damage.
    Riccioni G
    Cardiovasc Ther; 2011 Feb; 29(1):77-87. PubMed ID: 21106033
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The role of the renin-angiotensin-aldosterone system in cardiovascular progenitor cell function.
    Qian C; Schoemaker RG; van Gilst WH; Roks AJ
    Clin Sci (Lond); 2009 Feb; 116(4):301-14. PubMed ID: 19138171
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Renin-angiotensin-aldosterone system blockade in high-risk hypertensive patients: current approaches and future trends.
    Gullapalli N; Bloch MJ; Basile J
    Ther Adv Cardiovasc Dis; 2010 Dec; 4(6):359-73. PubMed ID: 20965951
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Inhibition of the renin-angiotensin-aldosterone system to prevent ischemic and atherothrombotic events.
    Papademetriou V
    Am Heart J; 2009 Jun; 157(6 Suppl):S24-30. PubMed ID: 19450721
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Renin-angiotensin-aldosterone system inhibitors and electrolyte disturbances].
    Kato H; Kobayashi K; Uchida S
    Nihon Rinsho; 2012 Sep; 70(9):1536-41. PubMed ID: 23012800
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [The renin-angiotensin-aldosterone system, angiotensin I converting enzyme, and the ACE-inhibitors. Historical perspective and recent findings].
    Gensini GF; Lippi D; Conti AA
    Recenti Prog Med; 2002 Oct; 93(10):544-53. PubMed ID: 12405014
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Role of angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, and aldosterone antagonists in the prevention of atrial and ventricular arrhythmias.
    Makkar KM; Sanoski CA; Spinler SA
    Pharmacotherapy; 2009 Jan; 29(1):31-48. PubMed ID: 19113795
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The evolving landscape of RAAS inhibition: from ACE inhibitors to ARBs, to DRIs and beyond.
    Epstein BJ; Leonard PT; Shah NK
    Expert Rev Cardiovasc Ther; 2012 Jun; 10(6):713-25. PubMed ID: 22894628
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The renin-angiotensin-aldosterone system and fibrinolysis.
    Felmeden DC; Lip GY
    J Renin Angiotensin Aldosterone Syst; 2000 Sep; 1(3):240-4. PubMed ID: 11881031
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Hypertension mega-trials with cardiovascular end points: effect of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers.
    Kjeldsen SE; Julius S
    Am Heart J; 2004 Nov; 148(5):747-54. PubMed ID: 15523303
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Dual blockade of the renin-angiotensin-aldosterone system: beyond the ACE inhibitor and angiotensin-II receptor blocker combination.
    Bomback AS; Toto R
    Am J Hypertens; 2009 Oct; 22(10):1032-40. PubMed ID: 19661925
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Insulin and the renin-angiotensin-aldosterone system: influence of ACE inhibition.
    Ferrannini E; Seghieri G; Muscelli E
    J Cardiovasc Pharmacol; 1994; 24 Suppl 3():S61-9. PubMed ID: 7700069
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.